Department of Urology 7, Gonda, Mayo Clinic Rochester, MN 55905, USA.
Ther Adv Urol. 2009 Apr;1(1):5-11. doi: 10.1177/1756287209104163.
To review the incidence and risks of bladder cancer following gastrointestinal augmentations done for congenial anomalies in childhood.
A literature search using PubMed and Ovid Medline search engines was performed. MeSH terms evaluated were; bladder augmentations, enterocystoplasty, gastrocystoplasty, spina bifida, spinal dysraphism, myelodysplasia, neural tube defects, posterior urethral valves and bladder exstrophy were cross referenced with the terms, bladder cancer and urinary bladder neoplasm. All patients who developed a bladder cancer following a bladder augmentation for a congenital anomaly were reviewed.
A total of 20 cases of bladder cancer following augmentations for congential anomalies, were identified, 9 arose following ileal cystoplasty, 3 following colocystolasty and 8 following gastrocystoplasty. The incidence of cancer developing per decade following surgery was 1.5% for ileal/colonic and 2.8% for gastric bladder augmentations. The majority of cancers developing within the augmented bladder are at advanced stages at the time of diagnosis (60%; 12/20 cases were ≥T3 at diagnosis). Several of the cases that developed occurred in patients exposed to known carcinogenic stimuli and/or arose in bladders with a known predisposition to carcinoma.
Patients augmented with ileal or colonic segment for a congenital bladder anomaly have a 7-8 fold and gastric augments a 14-15 fold increased risk for the development of bladder cancer over standard norms. Published data is however unable to determine if gastrointestinal bladder augmentation is an independent risk factor for cancer over the inherent risk of cancer arising from a congenitally abnormal bladder.
回顾儿童先天性异常行胃肠道增容术后膀胱癌的发病率和风险。
使用 PubMed 和 Ovid Medline 搜索引擎进行文献检索。评估的 MeSH 术语为;膀胱增容术、肠膀胱成形术、胃膀胱成形术、脊柱裂、脊髓脊膜发育不良、骨髓发育不全、神经管缺陷、后尿道瓣膜和膀胱外翻,并与膀胱肿瘤和膀胱癌等术语交叉引用。回顾了所有因先天性异常行膀胱增容术后发生膀胱癌的患者。
共确定了 20 例先天性异常行增容术后膀胱癌病例,其中 9 例发生在回肠膀胱成形术后,3 例发生在结肠膀胱成形术后,8 例发生在胃膀胱成形术后。术后每十年发生癌症的发病率分别为 1.5%(回肠/结肠)和 2.8%(胃膀胱)。在诊断时,大多数在增容膀胱中发展的癌症已处于晚期(60%;20 例中有 12 例在诊断时≥T3)。一些发生的病例发生在暴露于已知致癌刺激物的患者中,或发生在已知易患膀胱癌的膀胱中。
因先天性膀胱异常而接受回肠或结肠段增容的患者发生膀胱癌的风险增加 7-8 倍,接受胃增容的患者发生膀胱癌的风险增加 14-15 倍,高于标准正常值。然而,已有数据无法确定胃肠道膀胱增容术是否是先天性异常膀胱发生癌症的独立风险因素,还是癌症固有风险的增加。